Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

Jennet Harvey, Gary M. Clark, C. Kent Osborne et al. · Journal of Clinical Oncology · 1999 · 2.1K citations

Medicine, Endocrinology, Oncology +17

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

Constantine S. Mitsiades, Nicholas Mitsiades, Ciaran J. McMullan et al. · Cancer Cell · 2004 · 611 citations

Medicine, Hematology, Oncology +17

NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity

Leszek Wojnowski, Bettina Kulle, Markus Schirmer et al. · Circulation · 2005 · 488 citations

Medicine, Genetics, Oncology +17

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

Henk Visscher, Colin J.D. Ross, Shahrad R. Rassekh et al. · Journal of Clinical Oncology · 2011 · 394 citations · Full text

Medicine, Genetics, Oncology +17